#AAO22: In bid for first FDA nod in ge­o­graph­ic at­ro­phy, Apel­lis claims an­oth­er first in eye dis­ease field

CHICA­GO — Eight weeks be­fore pa­tients and in­dus­try find out if the FDA ap­proves the first treat­ment for ge­o­graph­ic at­ro­phy, an ad­vanced form of age-re­lat­ed mac­u­lar de­gen­er­a­tion, the biotech be­hind the drug is out with some new da­ta on a sec­ondary end­point.

In what study in­ves­ti­ga­tor Charles Wykoff called the “first di­rect ev­i­dence of func­tion preser­va­tion by slow­ing GA growth” in an in­ves­ti­ga­tion­al treat­ment, Apel­lis Phar­ma­ceu­ti­cals’ drug pegc­eta­coplan led to less loss of reti­nal sen­si­tiv­i­ty ver­sus sham  with­in 250 mi­crons on ei­ther side of the GA le­sion over 24 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER